In ovarian cancer preclinical models, b-AP15 has shown capability to inhibit survival of TP53 mutant cells by regulation of TGF-β signaling as a consequence of UCHL5 blockade and Smad2 phosphorylation resulting in apoptosis. Here, TP53 is linked to ovarian carcinoma.